These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 25219817)
1. Pharmacotherapy targeting the EGFR oncogene in NSCLC. Landi L; Cappuzzo F Expert Opin Pharmacother; 2014 Nov; 15(16):2293-305. PubMed ID: 25219817 [TBL] [Abstract][Full Text] [Related]
2. Protein kinase inhibitors to treat non-small-cell lung cancer. Minuti G; D'Incecco A; Landi L; Cappuzzo F Expert Opin Pharmacother; 2014 Jun; 15(9):1203-13. PubMed ID: 24745764 [TBL] [Abstract][Full Text] [Related]
3. Experience with erlotinib in the treatment of non-small cell lung cancer. Landi L; Cappuzzo F Ther Adv Respir Dis; 2015 Aug; 9(4):146-63. PubMed ID: 26063687 [TBL] [Abstract][Full Text] [Related]
4. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review. Murphy M; Stordal B Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938 [TBL] [Abstract][Full Text] [Related]
5. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer. Zhang K; Yuan Q J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005 [TBL] [Abstract][Full Text] [Related]
6. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era? Ou SH; Soo RA Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839 [TBL] [Abstract][Full Text] [Related]
7. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. Tan CS; Cho BC; Soo RA Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616 [TBL] [Abstract][Full Text] [Related]
9. The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer. Stinchcombe TE Curr Treat Options Oncol; 2016 Apr; 17(4):18. PubMed ID: 26961971 [TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR. Mitsuoka S; Kawaguchi T; Kubo A; Isa S; Asai K; Uji M; Watanabe T; Sawa K; Yoshimoto N; Oka T; Nakai T; Suzumura T; Tanaka H; Matsuura K; Kimura T; Yoshimura N; Kudoh S; Hirata K Expert Opin Pharmacother; 2016; 17(2):193-203. PubMed ID: 26781399 [TBL] [Abstract][Full Text] [Related]
11. Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC. Somasundaram A; Socinski MA; Burns TF Expert Opin Pharmacother; 2014 Dec; 15(18):2693-708. PubMed ID: 25381900 [TBL] [Abstract][Full Text] [Related]
12. Emerging treatment for advanced lung cancer with EGFR mutation. Inal C; Yilmaz E; Piperdi B; Perez-Soler R; Cheng H Expert Opin Emerg Drugs; 2015; 20(4):597-612. PubMed ID: 26153235 [TBL] [Abstract][Full Text] [Related]
13. Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. Neal JW; Heist RS; Fidias P; Temel JS; Huberman M; Marcoux JP; Muzikansky A; Lynch TJ; Sequist LV J Thorac Oncol; 2010 Nov; 5(11):1855-8. PubMed ID: 20975380 [TBL] [Abstract][Full Text] [Related]
14. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. Kanda S; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Kubota K; Tamura T; Ohe Y Lung Cancer; 2015 Sep; 89(3):287-93. PubMed ID: 26169499 [TBL] [Abstract][Full Text] [Related]
15. A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives. Russo A; Franchina T; Ricciardi GR; Picone A; Ferraro G; Zanghì M; Toscano G; Giordano A; Adamo V Oncotarget; 2015 Sep; 6(29):26814-25. PubMed ID: 26308162 [TBL] [Abstract][Full Text] [Related]
16. Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs. Brückl W; Tufman A; Huber RM Expert Rev Anticancer Ther; 2017 Feb; 17(2):143-155. PubMed ID: 27898252 [TBL] [Abstract][Full Text] [Related]
17. [Advances in research on primary resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer patients]. Yao YF; Wang J; Wang BC Zhonghua Zhong Liu Za Zhi; 2016 Nov; 38(11):801-805. PubMed ID: 27998436 [TBL] [Abstract][Full Text] [Related]
18. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs. Sheng Z; Zhang Y Am J Clin Oncol; 2017 Aug; 40(4):362-369. PubMed ID: 25647830 [TBL] [Abstract][Full Text] [Related]